DDInter1285 DDInter1676
A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Nevirapine {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Nevirapine {u} (Compound) binds {v} (Gene) CYP3A5
Nevirapine {u} (Compound) is included by {v} (Pharmacologic Class) Non-Nucleoside Reverse Transcriptase Inhibitors
Nevirapine {u} (Compound) causes {v} (Side Effect) Hypersensitive syndrome
Nevirapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Prasugrel
Nevirapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Nevirapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisapride
Nevirapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pegaspargase
Nevirapine {u} may lead to a major life threatening interaction when taken with {v} Brigatinib
Nevirapine (Compound) treats acquired immunodeficiency syndrome (Disease)
Nevirapine (Compound) binds CYP3A5 (Gene)
Nevirapine (Compound) is included by Non-Nucleoside Reverse Transcriptase Inhibitors (Pharmacologic Class)
Nevirapine (Compound) causes Hypersensitive syndrome (Side Effect)
Nevirapine may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Nevirapine may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Cisapride
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase
Nevirapine may lead to a major life threatening interaction when taken with Brigatinib